• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

相似文献

1
Unexpected decline in survival from amyotrophic lateral sclerosis/motor neurone disease.肌萎缩侧索硬化症/运动神经元病患者生存率意外下降。
J Neurol Neurosurg Psychiatry. 2004 Dec;75(12):1753-5. doi: 10.1136/jnnp.2003.024364.
2
The epidemiology of amyotrophic lateral sclerosis (ALS/MND) in people aged 80 or over.80岁及以上人群的肌萎缩侧索硬化症(ALS/MND)流行病学。
Age Ageing. 2004 Mar;33(2):131-4. doi: 10.1093/ageing/afh013.
3
Frequency, timing and outcome of gastrostomy tubes for amyotrophic lateral sclerosis/motor neurone disease--a record linkage study from the Scottish Motor Neurone Disease Register.肌萎缩侧索硬化症/运动神经元病胃造瘘管置入的频率、时间及结果——一项基于苏格兰运动神经元病登记处的记录链接研究
J Neurol. 2004 Jul;251(7):813-7. doi: 10.1007/s00415-004-0429-9.
4
Identifying who will benefit from non-invasive ventilation in amyotrophic lateral sclerosis/motor neurone disease in a clinical cohort.在临床队列中识别哪些肌萎缩侧索硬化症/运动神经元病患者将从无创通气中受益。
J Neurol Neurosurg Psychiatry. 2016 Mar;87(3):280-6. doi: 10.1136/jnnp-2014-310055. Epub 2015 Apr 9.
5
Improved survival and 30-day mortality after gastrostomy in Scottish motor neurone disease patients: evidence from a national retrospective cohort study using STROBE criteria.苏格兰运动神经元病患者胃造口术后生存时间和 30 天死亡率的改善:基于 STROBE 标准的全国回顾性队列研究证据。
Amyotroph Lateral Scler Frontotemporal Degener. 2019 May;20(3-4):165-171. doi: 10.1080/21678421.2019.1570271. Epub 2019 Mar 5.
6
Riluzole for amyotrophic lateral sclerosis (ALS)/motor neuron disease (MND).利鲁唑用于治疗肌萎缩侧索硬化症(ALS)/运动神经元病(MND)。
Amyotroph Lateral Scler Other Motor Neuron Disord. 2003 Sep;4(3):191-206.
7
Riluzole and amyotrophic lateral sclerosis survival: a population-based study in southern Italy.利鲁唑与肌萎缩侧索硬化症患者的生存情况:意大利南部的一项基于人群的研究。
Eur J Neurol. 2007 Mar;14(3):262-8. doi: 10.1111/j.1468-1331.2006.01575.x.
8
Cause of death and clinical grading criteria in a cohort of amyotrophic lateral sclerosis cases undergoing autopsy from the Scottish Motor Neurone Disease Register.来自苏格兰运动神经元疾病登记处的一组接受尸检的肌萎缩侧索硬化症病例的死亡原因及临床分级标准。
J Neurol Neurosurg Psychiatry. 2009 Jan;80(1):84-7. doi: 10.1136/jnnp.2008.149708.
9
Motor axonal excitability properties are strong predictors for survival in amyotrophic lateral sclerosis.运动轴突兴奋性特征是肌萎缩侧索硬化生存的有力预测指标。
J Neurol Neurosurg Psychiatry. 2012 Jul;83(7):734-8. doi: 10.1136/jnnp-2011-301782. Epub 2012 May 7.
10
Analysis of survival and prognostic factors in amyotrophic lateral sclerosis: a population based study.肌萎缩侧索硬化症生存及预后因素分析:一项基于人群的研究
J Neurol Neurosurg Psychiatry. 2008 Jan;79(1):33-7. doi: 10.1136/jnnp.2007.118018. Epub 2007 Jun 5.

引用本文的文献

1
Changes to Average Survival of Patients With Amyotrophic Lateral Sclerosis (1995-2018): Results From the Piemonte and Valle d'Aosta Registry.肌萎缩侧索硬化症患者平均生存期的变化(1995 - 2018年):皮埃蒙特和瓦莱达奥斯塔登记处的结果
Neurology. 2025 Apr 22;104(8):e213467. doi: 10.1212/WNL.0000000000213467. Epub 2025 Mar 24.
2
Retrospective longitudinal study of ALS in Cyprus: Clinical characteristics, management and survival.塞浦路斯肌萎缩侧索硬化症的回顾性纵向研究:临床特征、治疗和生存。
PLoS One. 2019 Sep 6;14(9):e0220246. doi: 10.1371/journal.pone.0220246. eCollection 2019.
3
Machine Learning in Amyotrophic Lateral Sclerosis: Achievements, Pitfalls, and Future Directions.肌萎缩侧索硬化症中的机器学习:成就、陷阱与未来方向。
Front Neurosci. 2019 Feb 28;13:135. doi: 10.3389/fnins.2019.00135. eCollection 2019.
4
Variation in worldwide incidence of amyotrophic lateral sclerosis: a meta-analysis.肌萎缩侧索硬化症全球发病率的差异:一项荟萃分析。
Int J Epidemiol. 2017 Feb 1;46(1):57-74. doi: 10.1093/ije/dyw061.
5
A Temporal Association between Accumulated Petrol (Gasoline) Lead Emissions and Motor Neuron Disease in Australia.澳大利亚累积汽油铅排放与运动神经元病之间的时间关联。
Int J Environ Res Public Health. 2015 Dec 19;12(12):16124-35. doi: 10.3390/ijerph121215047.
6
Stratification of ALS patients' survival: a population-based study.肌萎缩侧索硬化症患者生存情况分层:一项基于人群的研究。
J Neurol. 2016 Jan;263(1):100-11. doi: 10.1007/s00415-015-7940-z. Epub 2015 Oct 30.
7
Prognostic Factors in Amyotrophic Lateral Sclerosis: A Population-Based Study.肌萎缩侧索硬化症的预后因素:一项基于人群的研究。
PLoS One. 2015 Oct 30;10(10):e0141500. doi: 10.1371/journal.pone.0141500. eCollection 2015.
8
Clinical and demographic factors and outcome of amyotrophic lateral sclerosis in relation to population ancestral origin.与人口祖籍有关的肌萎缩侧索硬化的临床和人口统计学因素及结果。
Eur J Epidemiol. 2016 Mar;31(3):229-45. doi: 10.1007/s10654-015-0090-x. Epub 2015 Oct 12.
9
The effect of autologous bone marrow mononuclear cell transplantation on the survival duration in Amyotrophic Lateral Sclerosis - a retrospective controlled study.自体骨髓单个核细胞移植对肌萎缩侧索硬化症患者生存时间的影响——一项回顾性对照研究
Am J Stem Cells. 2015 Mar 15;4(1):50-65. eCollection 2015.
10
Feasibility of creating a National ALS Registry using administrative data in the United States.利用美国行政数据创建全国肌萎缩侧索硬化症登记处的可行性。
Amyotroph Lateral Scler Frontotemporal Degener. 2014 Sep;15(5-6):433-9. doi: 10.3109/21678421.2014.887119. Epub 2014 Mar 6.

肌萎缩侧索硬化症/运动神经元病患者生存率意外下降。

Unexpected decline in survival from amyotrophic lateral sclerosis/motor neurone disease.

作者信息

Forbes R B, Colville S, Cran G W, Swingler R J

机构信息

Department of Neurology, Ninewells Hospital and Medical School, Dundee, Scotland, UK.

出版信息

J Neurol Neurosurg Psychiatry. 2004 Dec;75(12):1753-5. doi: 10.1136/jnnp.2003.024364.

DOI:10.1136/jnnp.2003.024364
PMID:15548498
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC1738850/
Abstract

OBJECTIVES

To describe survival of 1226 Scottish adults with amyotrophic lateral sclerosis/motor neurone disease (ALS/MND).

METHODS

Ten year, prospective, population based disease register. Cox time dependent proportional hazards modelling for multivariate survival analyses.

RESULTS

Median survival from onset was 25 months (interquartile range 16-34 months). In multivariate models we found an increased hazard with more recently diagnosed cases-that is, there was an unexpected decline in survival over the 10 year period (hazard ratio (HR) 1.06 (95% CI 1.04 to 1.09). Positive effects on survival were demonstrated for longer time from onset to diagnosis (HR 0.38 (95% CI 0.33 to 0.42), assessment by a neurological specialist (HR 0.56 (95% CI 0.40 to 0.77), and treatment with riluzole (HR 0.24 (95% CI 0.14 to 0.42). Poor prognosis was associated with bulbar onset (HR 1.25 (95% CI 1.09 to 1.46) and a mixed lower and upper motor neurone syndrome (HR 1.23 (95% CI 1.01-1.49) and increasing age.

CONCLUSIONS

We found an unexpected decline in survival over the 10 year period, despite controlling for potential confounding variables. We would be cautious about over-interpreting these observations and suggest that further research is required to confirm or refute these findings.

摘要

目的

描述1226名患有肌萎缩侧索硬化症/运动神经元病(ALS/MND)的苏格兰成年人的生存率。

方法

基于人群的前瞻性疾病登记,为期十年。采用Cox时间依赖性比例风险模型进行多变量生存分析。

结果

从发病起的中位生存期为25个月(四分位间距为16 - 34个月)。在多变量模型中,我们发现近期确诊的病例风险增加,即在这10年期间生存率意外下降(风险比(HR)为1.06(95%置信区间为1.04至1.09)。从发病到诊断的时间更长对生存有积极影响(HR为0.38(95%置信区间为0.33至0.42),由神经科专家进行评估(HR为0.56(95%置信区间为0.40至0.77),以及使用利鲁唑治疗(HR为0.24(95%置信区间为0.14至0.42)。预后不良与延髓发病(HR为1.25(95%置信区间为1.09至1.46)、上下运动神经元混合综合征(HR为1.23(95%置信区间为1.01 - 1.49)以及年龄增加有关。

结论

尽管控制了潜在的混杂变量,但我们发现这10年期间生存率意外下降。我们对过度解读这些观察结果持谨慎态度,并建议需要进一步研究来证实或反驳这些发现。